Crocetti Emanuele, Guzzinati Stefano, Paci Eugenio, Falcini Fabio, Zanetti Roberto, Vercelli Marina, Rashid Ivan, De Lisi Vincenzo, Russo Antonio, Vitarelli Susanna, Ferretti Stefano, Mangone Lucia, Cesaraccio Rosaria, Tumino Rosario, Pannozzo Fabio
Tuscany Cancer Registry, Clinical and Descriptive Epidemiology Unit, CSPO, Florence, Italy.
Melanoma Res. 2008 Jun;18(3):230-4. doi: 10.1097/CMR.0b013e3282fafd0a.
The aim of this study was to provide further quantitative data on the risk of second nonmelanoma cancers in patients with cutaneous malignant melanoma (CMM). A cohort of 14 560 population-based patients from the Italian Network of Cancer Registries incident during 1985-2002 were included and followed up for further incident cases and vital status. Standardized incidence ratios (SIR) were used to compare the number of observed second cancers with expected cancers. In a total of 69 581 person-years, 1020 second cancers were registered, of which 804.6 were expected (SIR=1.27; 95% confidence interval 1.19-1.35). The risk was similar for males and females, (SIR=1.27 and 1.26, respectively). The risk was slightly higher among younger (<60 years; SIR=1.44) than older (60+ years; SIR=1.19) patients. The overall risk in the period after CMM diagnosis did not change significantly (SIR=1.34 during the first 5 years and 1.12 afterwards). No differences in the overall risk were evident in different years of diagnosis, for different melanoma morphology types or for different geographical areas within Italy. Statistically significantly increased risks were found for nonmelanoma skin cancers [observed number (n)=362, SIR=3.12], for bone (n=5, SIR=6.08) and for kidney cancers (n=39, SIR=1.95) and lower than expected risks were found for liver (SIR=0.46) and lung cancers (SIR=0.71). We confirm that CMM patients are at high risk for nonmelanoma skin cancers. The reasons for the increased risk of kidney and bone cancers are not yet clear.
本研究的目的是提供关于皮肤恶性黑色素瘤(CMM)患者发生第二种非黑色素瘤癌症风险的更多定量数据。纳入了意大利癌症登记网络中1985年至2002年间发病的14560名基于人群的患者队列,并对后续的发病病例和生命状态进行随访。使用标准化发病比(SIR)来比较观察到的第二种癌症数量与预期癌症数量。在总共69581人年中,登记了1020例第二种癌症,其中预期为804.6例(SIR = 1.27;95%置信区间1.19 - 1.35)。男性和女性的风险相似(分别为SIR = 1.27和1.26)。年轻患者(<60岁;SIR = 1.44)的风险略高于老年患者(60岁及以上;SIR = 1.19)。CMM诊断后的总体风险在不同年份没有显著变化(前5年SIR = 1.34,之后为1.12)。在不同诊断年份、不同黑色素瘤形态类型或意大利不同地理区域,总体风险没有明显差异。非黑色素瘤皮肤癌(观察到的数量(n)= 362,SIR = 3.12)、骨癌(n = 5,SIR = 6.08)和肾癌(n = 39,SIR = 1.95)的风险在统计学上显著增加,而肝癌(SIR = 0.46)和肺癌(SIR = 0.71)的风险低于预期。我们证实CMM患者发生非黑色素瘤皮肤癌的风险很高。肾癌和骨癌风险增加的原因尚不清楚。